nodes	percent_of_prediction	percent_of_DWPC	metapath
Crizotinib—MET—ovarian cancer	0.312	0.895	CbGaD
Crizotinib—AURKA—Epirubicin—ovarian cancer	0.145	0.541	CbGbCtD
Crizotinib—AURKA—Doxorubicin—ovarian cancer	0.077	0.288	CbGbCtD
Crizotinib—ABCB1—ovarian cancer	0.0364	0.105	CbGaD
Crizotinib—ABCB1—Topotecan—ovarian cancer	0.00784	0.0293	CbGbCtD
Crizotinib—CYP3A5—Paclitaxel—ovarian cancer	0.00596	0.0223	CbGbCtD
Crizotinib—ABCB1—Vinorelbine—ovarian cancer	0.00552	0.0206	CbGbCtD
Crizotinib—CYP3A4—Topotecan—ovarian cancer	0.0047	0.0176	CbGbCtD
Crizotinib—CYP3A5—Docetaxel—ovarian cancer	0.00431	0.0161	CbGbCtD
Crizotinib—ABCB1—Paclitaxel—ovarian cancer	0.00388	0.0145	CbGbCtD
Crizotinib—CYP3A4—Vinorelbine—ovarian cancer	0.00331	0.0124	CbGbCtD
Crizotinib—ABCB1—Docetaxel—ovarian cancer	0.00281	0.0105	CbGbCtD
Crizotinib—CYP3A4—Paclitaxel—ovarian cancer	0.00233	0.00869	CbGbCtD
Crizotinib—ABCB1—Doxorubicin—ovarian cancer	0.00209	0.00782	CbGbCtD
Crizotinib—CYP3A4—Docetaxel—ovarian cancer	0.00168	0.00628	CbGbCtD
Crizotinib—CYP3A4—Doxorubicin—ovarian cancer	0.00125	0.00468	CbGbCtD
Crizotinib—CASK—Irinotecan—Topotecan—ovarian cancer	0.000571	0.162	CbGdCrCtD
Crizotinib—IGF1R—Irinotecan—Topotecan—ovarian cancer	0.000537	0.152	CbGdCrCtD
Crizotinib—PTK2—Irinotecan—Topotecan—ovarian cancer	0.000456	0.13	CbGdCrCtD
Crizotinib—AURKA—Chlorambucil—Melphalan—ovarian cancer	0.000318	0.0902	CbGdCrCtD
Crizotinib—AURKA—Irinotecan—Topotecan—ovarian cancer	0.000221	0.0627	CbGdCrCtD
Crizotinib—LCK—uterus—ovarian cancer	0.000171	0.00147	CbGeAlD
Crizotinib—STK35—female gonad—ovarian cancer	0.000171	0.00147	CbGeAlD
Crizotinib—BMP2K—bone marrow—ovarian cancer	0.000171	0.00147	CbGeAlD
Crizotinib—FES—lymph node—ovarian cancer	0.000171	0.00147	CbGeAlD
Crizotinib—TAOK3—uterine cervix—ovarian cancer	0.000171	0.00147	CbGeAlD
Crizotinib—AXL—uterus—ovarian cancer	0.00017	0.00147	CbGeAlD
Crizotinib—EPHB6—decidua—ovarian cancer	0.00017	0.00147	CbGeAlD
Crizotinib—STK3—testis—ovarian cancer	0.00017	0.00147	CbGeAlD
Crizotinib—TIE1—testis—ovarian cancer	0.00017	0.00147	CbGeAlD
Crizotinib—STK35—vagina—ovarian cancer	0.00017	0.00146	CbGeAlD
Crizotinib—MAP3K3—endometrium—ovarian cancer	0.000169	0.00146	CbGeAlD
Crizotinib—MAP4K5—endometrium—ovarian cancer	0.000169	0.00146	CbGeAlD
Crizotinib—TEK—endometrium—ovarian cancer	0.000169	0.00146	CbGeAlD
Crizotinib—SRC—epithelium—ovarian cancer	0.000168	0.00144	CbGeAlD
Crizotinib—EPHA4—female reproductive system—ovarian cancer	0.000168	0.00144	CbGeAlD
Crizotinib—ABL2—female gonad—ovarian cancer	0.000167	0.00143	CbGeAlD
Crizotinib—SRC—uterine cervix—ovarian cancer	0.000166	0.00143	CbGeAlD
Crizotinib—AURKA—testis—ovarian cancer	0.000166	0.00143	CbGeAlD
Crizotinib—ABL2—vagina—ovarian cancer	0.000166	0.00143	CbGeAlD
Crizotinib—PTK2B—bone marrow—ovarian cancer	0.000165	0.00142	CbGeAlD
Crizotinib—BMP2K—female gonad—ovarian cancer	0.000165	0.00142	CbGeAlD
Crizotinib—YES1—decidua—ovarian cancer	0.000165	0.00142	CbGeAlD
Crizotinib—TESK1—testis—ovarian cancer	0.000164	0.00142	CbGeAlD
Crizotinib—MAP3K2—female reproductive system—ovarian cancer	0.000164	0.00141	CbGeAlD
Crizotinib—SLK—uterus—ovarian cancer	0.000164	0.00141	CbGeAlD
Crizotinib—BMP2K—vagina—ovarian cancer	0.000164	0.00141	CbGeAlD
Crizotinib—RIPK2—bone marrow—ovarian cancer	0.000164	0.00141	CbGeAlD
Crizotinib—STK10—decidua—ovarian cancer	0.000163	0.0014	CbGeAlD
Crizotinib—EPHB4—uterus—ovarian cancer	0.000163	0.0014	CbGeAlD
Crizotinib—JAK2—gonad—ovarian cancer	0.000163	0.0014	CbGeAlD
Crizotinib—TAOK3—decidua—ovarian cancer	0.000162	0.0014	CbGeAlD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Vinorelbine—ovarian cancer	0.000162	0.00162	CcSEcCtD
Crizotinib—Neuropathy peripheral—Paclitaxel—ovarian cancer	0.000162	0.00162	CcSEcCtD
Crizotinib—EPHB6—endometrium—ovarian cancer	0.000162	0.00139	CbGeAlD
Crizotinib—MET—lymph node—ovarian cancer	0.000161	0.00139	CbGeAlD
Crizotinib—Dyspepsia—Topotecan—ovarian cancer	0.000161	0.00161	CcSEcCtD
Crizotinib—Paraesthesia—Melphalan—ovarian cancer	0.000161	0.00161	CcSEcCtD
Crizotinib—PTK2—female reproductive system—ovarian cancer	0.000161	0.00139	CbGeAlD
Crizotinib—TBK1—female reproductive system—ovarian cancer	0.000161	0.00139	CbGeAlD
Crizotinib—Fluid retention—Epirubicin—ovarian cancer	0.00016	0.0016	CcSEcCtD
Crizotinib—Alanine aminotransferase increased—Docetaxel—ovarian cancer	0.00016	0.0016	CcSEcCtD
Crizotinib—Gait disturbance—Doxorubicin—ovarian cancer	0.00016	0.0016	CcSEcCtD
Crizotinib—MERTK—testis—ovarian cancer	0.00016	0.00138	CbGeAlD
Crizotinib—Dyspnoea—Melphalan—ovarian cancer	0.00016	0.0016	CcSEcCtD
Crizotinib—TYK2—female reproductive system—ovarian cancer	0.00016	0.00138	CbGeAlD
Crizotinib—Decreased appetite—Topotecan—ovarian cancer	0.000159	0.00159	CcSEcCtD
Crizotinib—PTK2B—female gonad—ovarian cancer	0.000159	0.00137	CbGeAlD
Crizotinib—Neuropathy—Epirubicin—ovarian cancer	0.000159	0.00159	CcSEcCtD
Crizotinib—SRC—decidua—ovarian cancer	0.000158	0.00136	CbGeAlD
Crizotinib—Gastrointestinal disorder—Topotecan—ovarian cancer	0.000158	0.00158	CcSEcCtD
Crizotinib—PTK2B—vagina—ovarian cancer	0.000158	0.00136	CbGeAlD
Crizotinib—Fatigue—Topotecan—ovarian cancer	0.000158	0.00158	CcSEcCtD
Crizotinib—Dyspepsia—Melphalan—ovarian cancer	0.000158	0.00158	CcSEcCtD
Crizotinib—IRAK1—female reproductive system—ovarian cancer	0.000158	0.00136	CbGeAlD
Crizotinib—RIPK2—female gonad—ovarian cancer	0.000158	0.00136	CbGeAlD
Crizotinib—MAP4K5—gonad—ovarian cancer	0.000157	0.00135	CbGeAlD
Crizotinib—MAP3K3—gonad—ovarian cancer	0.000157	0.00135	CbGeAlD
Crizotinib—RIPK2—vagina—ovarian cancer	0.000157	0.00135	CbGeAlD
Crizotinib—Constipation—Topotecan—ovarian cancer	0.000157	0.00157	CcSEcCtD
Crizotinib—LIMK2—testis—ovarian cancer	0.000157	0.00135	CbGeAlD
Crizotinib—Hepatobiliary disease—Paclitaxel—ovarian cancer	0.000156	0.00156	CcSEcCtD
Crizotinib—Pulmonary embolism—Doxorubicin—ovarian cancer	0.000156	0.00156	CcSEcCtD
Crizotinib—Phosphatase alkaline increased—Doxorubicin—ovarian cancer	0.000156	0.00156	CcSEcCtD
Crizotinib—YES1—endometrium—ovarian cancer	0.000156	0.00135	CbGeAlD
Crizotinib—CDK7—lymph node—ovarian cancer	0.000156	0.00134	CbGeAlD
Crizotinib—Decreased appetite—Melphalan—ovarian cancer	0.000156	0.00156	CcSEcCtD
Crizotinib—NUAK2—testis—ovarian cancer	0.000156	0.00134	CbGeAlD
Crizotinib—MAP4K5—uterus—ovarian cancer	0.000156	0.00134	CbGeAlD
Crizotinib—TEK—uterus—ovarian cancer	0.000156	0.00134	CbGeAlD
Crizotinib—Infection—Vinorelbine—ovarian cancer	0.000156	0.00156	CcSEcCtD
Crizotinib—MAP3K2—bone marrow—ovarian cancer	0.000155	0.00134	CbGeAlD
Crizotinib—Gastrointestinal disorder—Melphalan—ovarian cancer	0.000155	0.00155	CcSEcCtD
Crizotinib—MAP3K12—testis—ovarian cancer	0.000155	0.00133	CbGeAlD
Crizotinib—ACVR1—testis—ovarian cancer	0.000155	0.00133	CbGeAlD
Crizotinib—FLT3—testis—ovarian cancer	0.000155	0.00133	CbGeAlD
Crizotinib—TAOK2—lymph node—ovarian cancer	0.000155	0.00133	CbGeAlD
Crizotinib—RPS6KB1—female reproductive system—ovarian cancer	0.000155	0.00133	CbGeAlD
Crizotinib—Fatigue—Melphalan—ovarian cancer	0.000155	0.00155	CcSEcCtD
Crizotinib—TAOK3—endometrium—ovarian cancer	0.000154	0.00133	CbGeAlD
Crizotinib—FGR—female reproductive system—ovarian cancer	0.000154	0.00132	CbGeAlD
Crizotinib—Nervous system disorder—Vinorelbine—ovarian cancer	0.000154	0.00154	CcSEcCtD
Crizotinib—AXL—female reproductive system—ovarian cancer	0.000153	0.00132	CbGeAlD
Crizotinib—EPHA4—female gonad—ovarian cancer	0.000152	0.00131	CbGeAlD
Crizotinib—Skin disorder—Vinorelbine—ovarian cancer	0.000152	0.00152	CcSEcCtD
Crizotinib—TBK1—bone marrow—ovarian cancer	0.000152	0.00131	CbGeAlD
Crizotinib—STK35—testis—ovarian cancer	0.000152	0.00131	CbGeAlD
Crizotinib—ABL1—myometrium—ovarian cancer	0.000152	0.0013	CbGeAlD
Crizotinib—EPHA4—vagina—ovarian cancer	0.000152	0.0013	CbGeAlD
Crizotinib—Bradycardia—Paclitaxel—ovarian cancer	0.000151	0.00151	CcSEcCtD
Crizotinib—TYK2—bone marrow—ovarian cancer	0.000151	0.0013	CbGeAlD
Crizotinib—MAP3K2—female gonad—ovarian cancer	0.000149	0.00129	CbGeAlD
Crizotinib—CSF1R—uterine cervix—ovarian cancer	0.000149	0.00128	CbGeAlD
Crizotinib—ACVR1B—lymph node—ovarian cancer	0.000149	0.00128	CbGeAlD
Crizotinib—EPHA3—lymph node—ovarian cancer	0.000149	0.00128	CbGeAlD
Crizotinib—IRAK1—bone marrow—ovarian cancer	0.000149	0.00128	CbGeAlD
Crizotinib—Fluid retention—Doxorubicin—ovarian cancer	0.000148	0.00148	CcSEcCtD
Crizotinib—ABL2—testis—ovarian cancer	0.000148	0.00127	CbGeAlD
Crizotinib—Asthenia—Chlorambucil—ovarian cancer	0.000148	0.00148	CcSEcCtD
Crizotinib—Hypoaesthesia—Paclitaxel—ovarian cancer	0.000148	0.00148	CcSEcCtD
Crizotinib—Neutropenia—Docetaxel—ovarian cancer	0.000147	0.00147	CcSEcCtD
Crizotinib—Neuropathy—Doxorubicin—ovarian cancer	0.000147	0.00147	CcSEcCtD
Crizotinib—Sepsis—Epirubicin—ovarian cancer	0.000147	0.00147	CcSEcCtD
Crizotinib—Urinary tract disorder—Paclitaxel—ovarian cancer	0.000147	0.00147	CcSEcCtD
Crizotinib—EPHB4—female reproductive system—ovarian cancer	0.000146	0.00126	CbGeAlD
Crizotinib—TBK1—female gonad—ovarian cancer	0.000146	0.00126	CbGeAlD
Crizotinib—PTK2—female gonad—ovarian cancer	0.000146	0.00126	CbGeAlD
Crizotinib—Oedema peripheral—Paclitaxel—ovarian cancer	0.000146	0.00146	CcSEcCtD
Crizotinib—RPS6KB1—bone marrow—ovarian cancer	0.000146	0.00126	CbGeAlD
Crizotinib—BMP2K—testis—ovarian cancer	0.000146	0.00126	CbGeAlD
Crizotinib—ABL1—embryo—ovarian cancer	0.000146	0.00125	CbGeAlD
Crizotinib—TBK1—vagina—ovarian cancer	0.000146	0.00125	CbGeAlD
Crizotinib—PTK2—vagina—ovarian cancer	0.000146	0.00125	CbGeAlD
Crizotinib—Urethral disorder—Paclitaxel—ovarian cancer	0.000145	0.00146	CcSEcCtD
Crizotinib—TYK2—female gonad—ovarian cancer	0.000145	0.00125	CbGeAlD
Crizotinib—JAK2—female reproductive system—ovarian cancer	0.000145	0.00125	CbGeAlD
Crizotinib—FGR—bone marrow—ovarian cancer	0.000145	0.00125	CbGeAlD
Crizotinib—LCK—bone marrow—ovarian cancer	0.000145	0.00125	CbGeAlD
Crizotinib—YES1—gonad—ovarian cancer	0.000145	0.00125	CbGeAlD
Crizotinib—Body temperature increased—Topotecan—ovarian cancer	0.000145	0.00145	CcSEcCtD
Crizotinib—TYK2—vagina—ovarian cancer	0.000145	0.00124	CbGeAlD
Crizotinib—YES1—uterus—ovarian cancer	0.000144	0.00124	CbGeAlD
Crizotinib—EPHA2—female reproductive system—ovarian cancer	0.000144	0.00124	CbGeAlD
Crizotinib—STK10—gonad—ovarian cancer	0.000144	0.00124	CbGeAlD
Crizotinib—IRAK1—female gonad—ovarian cancer	0.000144	0.00124	CbGeAlD
Crizotinib—Visual impairment—Paclitaxel—ovarian cancer	0.000143	0.00143	CcSEcCtD
Crizotinib—STK10—uterus—ovarian cancer	0.000143	0.00123	CbGeAlD
Crizotinib—JAK3—lymph node—ovarian cancer	0.000142	0.00122	CbGeAlD
Crizotinib—Weight decreased—Docetaxel—ovarian cancer	0.000142	0.00142	CcSEcCtD
Crizotinib—CSF1R—decidua—ovarian cancer	0.000142	0.00122	CbGeAlD
Crizotinib—TAOK3—uterus—ovarian cancer	0.000142	0.00122	CbGeAlD
Crizotinib—DCLK1—lymph node—ovarian cancer	0.000141	0.00122	CbGeAlD
Crizotinib—PTK2B—testis—ovarian cancer	0.000141	0.00121	CbGeAlD
Crizotinib—Blood alkaline phosphatase increased—Epirubicin—ovarian cancer	0.000141	0.00141	CcSEcCtD
Crizotinib—Pneumonia—Docetaxel—ovarian cancer	0.000141	0.00141	CcSEcCtD
Crizotinib—RPS6KB1—female gonad—ovarian cancer	0.000141	0.00121	CbGeAlD
Crizotinib—Diarrhoea—Chlorambucil—ovarian cancer	0.000141	0.00141	CcSEcCtD
Crizotinib—Paraesthesia—Vinorelbine—ovarian cancer	0.000141	0.00141	CcSEcCtD
Crizotinib—PLK4—lymph node—ovarian cancer	0.000141	0.00121	CbGeAlD
Crizotinib—Hepatic function abnormal—Epirubicin—ovarian cancer	0.00014	0.0014	CcSEcCtD
Crizotinib—MAP3K3—female reproductive system—ovarian cancer	0.00014	0.00121	CbGeAlD
Crizotinib—MAP4K5—female reproductive system—ovarian cancer	0.00014	0.00121	CbGeAlD
Crizotinib—TEK—female reproductive system—ovarian cancer	0.00014	0.00121	CbGeAlD
Crizotinib—Infestation—Docetaxel—ovarian cancer	0.00014	0.0014	CcSEcCtD
Crizotinib—Infestation NOS—Docetaxel—ovarian cancer	0.00014	0.0014	CcSEcCtD
Crizotinib—RPS6KB1—vagina—ovarian cancer	0.00014	0.00121	CbGeAlD
Crizotinib—LCK—female gonad—ovarian cancer	0.00014	0.00121	CbGeAlD
Crizotinib—FGR—female gonad—ovarian cancer	0.00014	0.00121	CbGeAlD
Crizotinib—RIPK2—testis—ovarian cancer	0.00014	0.0012	CbGeAlD
Crizotinib—Dyspnoea—Vinorelbine—ovarian cancer	0.00014	0.0014	CcSEcCtD
Crizotinib—STK4—lymph node—ovarian cancer	0.00014	0.0012	CbGeAlD
Crizotinib—AXL—female gonad—ovarian cancer	0.000139	0.0012	CbGeAlD
Crizotinib—SRC—gonad—ovarian cancer	0.000139	0.0012	CbGeAlD
Crizotinib—SLK—bone marrow—ovarian cancer	0.000139	0.0012	CbGeAlD
Crizotinib—FGR—vagina—ovarian cancer	0.000139	0.0012	CbGeAlD
Crizotinib—LCK—vagina—ovarian cancer	0.000139	0.0012	CbGeAlD
Crizotinib—Eye disorder—Paclitaxel—ovarian cancer	0.000139	0.00139	CcSEcCtD
Crizotinib—AXL—vagina—ovarian cancer	0.000139	0.00119	CbGeAlD
Crizotinib—EPHB4—bone marrow—ovarian cancer	0.000138	0.00119	CbGeAlD
Crizotinib—Cardiac disorder—Paclitaxel—ovarian cancer	0.000138	0.00138	CcSEcCtD
Crizotinib—Neuropathy peripheral—Docetaxel—ovarian cancer	0.000137	0.00137	CcSEcCtD
Crizotinib—JAK2—bone marrow—ovarian cancer	0.000137	0.00118	CbGeAlD
Crizotinib—Hepatic failure—Epirubicin—ovarian cancer	0.000136	0.00137	CcSEcCtD
Crizotinib—Decreased appetite—Vinorelbine—ovarian cancer	0.000136	0.00136	CcSEcCtD
Crizotinib—Sepsis—Doxorubicin—ovarian cancer	0.000136	0.00136	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Vinorelbine—ovarian cancer	0.000135	0.00135	CcSEcCtD
Crizotinib—EPHA4—testis—ovarian cancer	0.000135	0.00116	CbGeAlD
Crizotinib—Fatigue—Vinorelbine—ovarian cancer	0.000135	0.00135	CcSEcCtD
Crizotinib—CSF1R—endometrium—ovarian cancer	0.000135	0.00116	CbGeAlD
Crizotinib—SLK—female gonad—ovarian cancer	0.000134	0.00116	CbGeAlD
Crizotinib—Constipation—Vinorelbine—ovarian cancer	0.000134	0.00134	CcSEcCtD
Crizotinib—Mediastinal disorder—Paclitaxel—ovarian cancer	0.000134	0.00134	CcSEcCtD
Crizotinib—SLK—vagina—ovarian cancer	0.000133	0.00115	CbGeAlD
Crizotinib—EPHB4—female gonad—ovarian cancer	0.000133	0.00115	CbGeAlD
Crizotinib—MAP3K2—testis—ovarian cancer	0.000133	0.00114	CbGeAlD
Crizotinib—Arrhythmia—Paclitaxel—ovarian cancer	0.000133	0.00133	CcSEcCtD
Crizotinib—Hepatobiliary disease—Docetaxel—ovarian cancer	0.000133	0.00133	CcSEcCtD
Crizotinib—EPHB4—vagina—ovarian cancer	0.000132	0.00114	CbGeAlD
Crizotinib—JAK2—female gonad—ovarian cancer	0.000132	0.00114	CbGeAlD
Crizotinib—MAP3K3—bone marrow—ovarian cancer	0.000132	0.00114	CbGeAlD
Crizotinib—MAP4K5—bone marrow—ovarian cancer	0.000132	0.00114	CbGeAlD
Crizotinib—FER—lymph node—ovarian cancer	0.000132	0.00114	CbGeAlD
Crizotinib—ALK—lymph node—ovarian cancer	0.000132	0.00114	CbGeAlD
Crizotinib—JAK2—vagina—ovarian cancer	0.000132	0.00113	CbGeAlD
Crizotinib—Asthenia—Topotecan—ovarian cancer	0.000131	0.00132	CcSEcCtD
Crizotinib—Vomiting—Chlorambucil—ovarian cancer	0.000131	0.00131	CcSEcCtD
Crizotinib—EPHA2—female gonad—ovarian cancer	0.000131	0.00113	CbGeAlD
Crizotinib—TNK1—lymph node—ovarian cancer	0.000131	0.00112	CbGeAlD
Crizotinib—Blood alkaline phosphatase increased—Doxorubicin—ovarian cancer	0.00013	0.00131	CcSEcCtD
Crizotinib—EPHA2—vagina—ovarian cancer	0.00013	0.00112	CbGeAlD
Crizotinib—PTK2—testis—ovarian cancer	0.00013	0.00112	CbGeAlD
Crizotinib—TBK1—testis—ovarian cancer	0.00013	0.00112	CbGeAlD
Crizotinib—Hepatic function abnormal—Doxorubicin—ovarian cancer	0.00013	0.0013	CcSEcCtD
Crizotinib—YES1—female reproductive system—ovarian cancer	0.000129	0.00111	CbGeAlD
Crizotinib—MAP4K1—lymph node—ovarian cancer	0.000129	0.00111	CbGeAlD
Crizotinib—BMPR1B—lymph node—ovarian cancer	0.000129	0.00111	CbGeAlD
Crizotinib—Malnutrition—Paclitaxel—ovarian cancer	0.000129	0.00129	CcSEcCtD
Crizotinib—TYK2—testis—ovarian cancer	0.000129	0.00111	CbGeAlD
Crizotinib—Asthenia—Melphalan—ovarian cancer	0.000129	0.00129	CcSEcCtD
Crizotinib—STK10—female reproductive system—ovarian cancer	0.000128	0.0011	CbGeAlD
Crizotinib—TAOK3—female reproductive system—ovarian cancer	0.000128	0.0011	CbGeAlD
Crizotinib—MAP4K5—female gonad—ovarian cancer	0.000128	0.0011	CbGeAlD
Crizotinib—MAP3K3—female gonad—ovarian cancer	0.000128	0.0011	CbGeAlD
Crizotinib—TEK—female gonad—ovarian cancer	0.000128	0.0011	CbGeAlD
Crizotinib—IRAK1—testis—ovarian cancer	0.000127	0.0011	CbGeAlD
Crizotinib—IGF1R—lymph node—ovarian cancer	0.000127	0.00109	CbGeAlD
Crizotinib—TNK2—lymph node—ovarian cancer	0.000127	0.00109	CbGeAlD
Crizotinib—MAP3K3—vagina—ovarian cancer	0.000127	0.00109	CbGeAlD
Crizotinib—MAP4K5—vagina—ovarian cancer	0.000127	0.00109	CbGeAlD
Crizotinib—Dysgeusia—Paclitaxel—ovarian cancer	0.000127	0.00127	CcSEcCtD
Crizotinib—Hepatic failure—Doxorubicin—ovarian cancer	0.000126	0.00126	CcSEcCtD
Crizotinib—Diarrhoea—Topotecan—ovarian cancer	0.000125	0.00125	CcSEcCtD
Crizotinib—CSF1R—gonad—ovarian cancer	0.000125	0.00108	CbGeAlD
Crizotinib—Hypoaesthesia—Docetaxel—ovarian cancer	0.000125	0.00125	CcSEcCtD
Crizotinib—MAP4K2—lymph node—ovarian cancer	0.000125	0.00108	CbGeAlD
Crizotinib—RPS6KB1—testis—ovarian cancer	0.000125	0.00108	CbGeAlD
Crizotinib—SRC—female reproductive system—ovarian cancer	0.000125	0.00107	CbGeAlD
Crizotinib—CSF1R—uterus—ovarian cancer	0.000124	0.00107	CbGeAlD
Crizotinib—Urinary tract disorder—Docetaxel—ovarian cancer	0.000124	0.00124	CcSEcCtD
Crizotinib—FGR—testis—ovarian cancer	0.000124	0.00107	CbGeAlD
Crizotinib—LCK—testis—ovarian cancer	0.000124	0.00107	CbGeAlD
Crizotinib—Body temperature increased—Vinorelbine—ovarian cancer	0.000124	0.00124	CcSEcCtD
Crizotinib—Oedema peripheral—Docetaxel—ovarian cancer	0.000124	0.00124	CcSEcCtD
Crizotinib—AXL—testis—ovarian cancer	0.000124	0.00106	CbGeAlD
Crizotinib—STK3—lymph node—ovarian cancer	0.000123	0.00106	CbGeAlD
Crizotinib—TIE1—lymph node—ovarian cancer	0.000123	0.00106	CbGeAlD
Crizotinib—Urethral disorder—Docetaxel—ovarian cancer	0.000123	0.00123	CcSEcCtD
Crizotinib—Diarrhoea—Melphalan—ovarian cancer	0.000123	0.00123	CcSEcCtD
Crizotinib—Diplopia—Epirubicin—ovarian cancer	0.000123	0.00123	CcSEcCtD
Crizotinib—Nausea—Chlorambucil—ovarian cancer	0.000122	0.00122	CcSEcCtD
Crizotinib—YES1—bone marrow—ovarian cancer	0.000122	0.00105	CbGeAlD
Crizotinib—EPHB6—female gonad—ovarian cancer	0.000122	0.00105	CbGeAlD
Crizotinib—Vision blurred—Paclitaxel—ovarian cancer	0.000122	0.00122	CcSEcCtD
Crizotinib—Visual impairment—Docetaxel—ovarian cancer	0.000121	0.00121	CcSEcCtD
Crizotinib—Dizziness—Topotecan—ovarian cancer	0.000121	0.00121	CcSEcCtD
Crizotinib—EPHB6—vagina—ovarian cancer	0.000121	0.00104	CbGeAlD
Crizotinib—STK10—bone marrow—ovarian cancer	0.000121	0.00104	CbGeAlD
Crizotinib—TAOK3—bone marrow—ovarian cancer	0.000121	0.00104	CbGeAlD
Crizotinib—AURKA—lymph node—ovarian cancer	0.00012	0.00103	CbGeAlD
Crizotinib—Anaemia—Paclitaxel—ovarian cancer	0.000119	0.00119	CcSEcCtD
Crizotinib—TESK1—lymph node—ovarian cancer	0.000119	0.00103	CbGeAlD
Crizotinib—SLK—testis—ovarian cancer	0.000119	0.00102	CbGeAlD
Crizotinib—Face oedema—Epirubicin—ovarian cancer	0.000118	0.00118	CcSEcCtD
Crizotinib—EPHB4—testis—ovarian cancer	0.000118	0.00102	CbGeAlD
Crizotinib—ABL1—uterine cervix—ovarian cancer	0.000118	0.00102	CbGeAlD
Crizotinib—YES1—female gonad—ovarian cancer	0.000118	0.00101	CbGeAlD
Crizotinib—Eye disorder—Docetaxel—ovarian cancer	0.000118	0.00118	CcSEcCtD
Crizotinib—JAK2—testis—ovarian cancer	0.000117	0.00101	CbGeAlD
Crizotinib—YES1—vagina—ovarian cancer	0.000117	0.00101	CbGeAlD
Crizotinib—Cardiac disorder—Docetaxel—ovarian cancer	0.000117	0.00117	CcSEcCtD
Crizotinib—STK10—female gonad—ovarian cancer	0.000117	0.001	CbGeAlD
Crizotinib—Vomiting—Topotecan—ovarian cancer	0.000117	0.00117	CcSEcCtD
Crizotinib—TAOK3—female gonad—ovarian cancer	0.000116	0.001	CbGeAlD
Crizotinib—STK10—vagina—ovarian cancer	0.000116	0.000999	CbGeAlD
Crizotinib—MERTK—lymph node—ovarian cancer	0.000116	0.000999	CbGeAlD
Crizotinib—EPHA2—testis—ovarian cancer	0.000116	0.000998	CbGeAlD
Crizotinib—Syncope—Paclitaxel—ovarian cancer	0.000116	0.00116	CcSEcCtD
Crizotinib—Leukopenia—Paclitaxel—ovarian cancer	0.000116	0.00116	CcSEcCtD
Crizotinib—TAOK3—vagina—ovarian cancer	0.000116	0.000995	CbGeAlD
Crizotinib—Rash—Topotecan—ovarian cancer	0.000116	0.00116	CcSEcCtD
Crizotinib—Dermatitis—Topotecan—ovarian cancer	0.000115	0.00115	CcSEcCtD
Crizotinib—Vomiting—Melphalan—ovarian cancer	0.000114	0.00114	CcSEcCtD
Crizotinib—Loss of consciousness—Paclitaxel—ovarian cancer	0.000114	0.00114	CcSEcCtD
Crizotinib—Diplopia—Doxorubicin—ovarian cancer	0.000113	0.00114	CcSEcCtD
Crizotinib—LIMK2—lymph node—ovarian cancer	0.000113	0.000977	CbGeAlD
Crizotinib—Mediastinal disorder—Docetaxel—ovarian cancer	0.000113	0.00113	CcSEcCtD
Crizotinib—SRC—female gonad—ovarian cancer	0.000113	0.000975	CbGeAlD
Crizotinib—Rash—Melphalan—ovarian cancer	0.000113	0.00113	CcSEcCtD
Crizotinib—MAP3K3—testis—ovarian cancer	0.000113	0.000974	CbGeAlD
Crizotinib—TEK—testis—ovarian cancer	0.000113	0.000974	CbGeAlD
Crizotinib—MAP4K5—testis—ovarian cancer	0.000113	0.000974	CbGeAlD
Crizotinib—NUAK2—lymph node—ovarian cancer	0.000113	0.000973	CbGeAlD
Crizotinib—Dermatitis—Melphalan—ovarian cancer	0.000113	0.00113	CcSEcCtD
Crizotinib—Asthenia—Vinorelbine—ovarian cancer	0.000112	0.00113	CcSEcCtD
Crizotinib—Arrhythmia—Docetaxel—ovarian cancer	0.000112	0.00112	CcSEcCtD
Crizotinib—ABL1—decidua—ovarian cancer	0.000112	0.000967	CbGeAlD
Crizotinib—ACVR1—lymph node—ovarian cancer	0.000112	0.000966	CbGeAlD
Crizotinib—MAP3K12—lymph node—ovarian cancer	0.000112	0.000966	CbGeAlD
Crizotinib—FLT3—lymph node—ovarian cancer	0.000112	0.000966	CbGeAlD
Crizotinib—CSF1R—female reproductive system—ovarian cancer	0.000112	0.000962	CbGeAlD
Crizotinib—Hypokalaemia—Epirubicin—ovarian cancer	0.000112	0.00112	CcSEcCtD
Crizotinib—Aspartate aminotransferase increased—Epirubicin—ovarian cancer	0.00011	0.00111	CcSEcCtD
Crizotinib—STK35—lymph node—ovarian cancer	0.00011	0.000947	CbGeAlD
Crizotinib—Face oedema—Doxorubicin—ovarian cancer	0.00011	0.0011	CcSEcCtD
Crizotinib—Malnutrition—Docetaxel—ovarian cancer	0.00011	0.0011	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.000109	0.00109	CcSEcCtD
Crizotinib—Nausea—Topotecan—ovarian cancer	0.000109	0.00109	CcSEcCtD
Crizotinib—Muscular weakness—Epirubicin—ovarian cancer	0.000108	0.00108	CcSEcCtD
Crizotinib—Alanine aminotransferase increased—Epirubicin—ovarian cancer	0.000108	0.00108	CcSEcCtD
Crizotinib—EPHB6—testis—ovarian cancer	0.000108	0.000931	CbGeAlD
Crizotinib—Diarrhoea—Vinorelbine—ovarian cancer	0.000107	0.00107	CcSEcCtD
Crizotinib—Dysgeusia—Docetaxel—ovarian cancer	0.000107	0.00107	CcSEcCtD
Crizotinib—ABL2—lymph node—ovarian cancer	0.000107	0.000922	CbGeAlD
Crizotinib—ABL1—endometrium—ovarian cancer	0.000107	0.000918	CbGeAlD
Crizotinib—Nausea—Melphalan—ovarian cancer	0.000107	0.00107	CcSEcCtD
Crizotinib—BMP2K—lymph node—ovarian cancer	0.000106	0.000911	CbGeAlD
Crizotinib—CSF1R—bone marrow—ovarian cancer	0.000106	0.000908	CbGeAlD
Crizotinib—Oedema—Paclitaxel—ovarian cancer	0.000105	0.00105	CcSEcCtD
Crizotinib—IGF1R—Idarubicin—Epirubicin—ovarian cancer	0.000105	0.0298	CbGdCrCtD
Crizotinib—Infection—Paclitaxel—ovarian cancer	0.000105	0.00105	CcSEcCtD
Crizotinib—YES1—testis—ovarian cancer	0.000104	0.000899	CbGeAlD
Crizotinib—Shock—Paclitaxel—ovarian cancer	0.000104	0.00104	CcSEcCtD
Crizotinib—Dizziness—Vinorelbine—ovarian cancer	0.000104	0.00104	CcSEcCtD
Crizotinib—STK10—testis—ovarian cancer	0.000104	0.000891	CbGeAlD
Crizotinib—Nervous system disorder—Paclitaxel—ovarian cancer	0.000103	0.00103	CcSEcCtD
Crizotinib—Hypokalaemia—Doxorubicin—ovarian cancer	0.000103	0.00103	CcSEcCtD
Crizotinib—TAOK3—testis—ovarian cancer	0.000103	0.000888	CbGeAlD
Crizotinib—Skin disorder—Paclitaxel—ovarian cancer	0.000102	0.00102	CcSEcCtD
Crizotinib—PTK2B—lymph node—ovarian cancer	0.000102	0.00088	CbGeAlD
Crizotinib—Aspartate aminotransferase increased—Doxorubicin—ovarian cancer	0.000102	0.00102	CcSEcCtD
Crizotinib—CSF1R—female gonad—ovarian cancer	0.000102	0.000876	CbGeAlD
Crizotinib—RIPK2—lymph node—ovarian cancer	0.000101	0.000873	CbGeAlD
Crizotinib—Anaemia—Docetaxel—ovarian cancer	0.000101	0.00101	CcSEcCtD
Crizotinib—CSF1R—vagina—ovarian cancer	0.000101	0.00087	CbGeAlD
Crizotinib—SRC—testis—ovarian cancer	0.0001	0.000865	CbGeAlD
Crizotinib—Alanine aminotransferase increased—Doxorubicin—ovarian cancer	0.0001	0.001	CcSEcCtD
Crizotinib—Muscular weakness—Doxorubicin—ovarian cancer	0.0001	0.001	CcSEcCtD
Crizotinib—Vomiting—Vinorelbine—ovarian cancer	9.97e-05	0.000997	CcSEcCtD
Crizotinib—Neutropenia—Epirubicin—ovarian cancer	9.91e-05	0.000992	CcSEcCtD
Crizotinib—ABL1—gonad—ovarian cancer	9.89e-05	0.000852	CbGeAlD
Crizotinib—Rash—Vinorelbine—ovarian cancer	9.88e-05	0.000989	CcSEcCtD
Crizotinib—Dermatitis—Vinorelbine—ovarian cancer	9.87e-05	0.000988	CcSEcCtD
Crizotinib—Upper respiratory tract infection—Epirubicin—ovarian cancer	9.85e-05	0.000986	CcSEcCtD
Crizotinib—ABL1—uterus—ovarian cancer	9.83e-05	0.000846	CbGeAlD
Crizotinib—Syncope—Docetaxel—ovarian cancer	9.82e-05	0.000983	CcSEcCtD
Crizotinib—Leukopenia—Docetaxel—ovarian cancer	9.8e-05	0.000981	CcSEcCtD
Crizotinib—EPHA4—lymph node—ovarian cancer	9.8e-05	0.000844	CbGeAlD
Crizotinib—IGF1R—Idarubicin—Doxorubicin—ovarian cancer	9.7e-05	0.0275	CbGdCrCtD
Crizotinib—Loss of consciousness—Docetaxel—ovarian cancer	9.62e-05	0.000963	CcSEcCtD
Crizotinib—MAP3K2—lymph node—ovarian cancer	9.61e-05	0.000827	CbGeAlD
Crizotinib—Weight decreased—Epirubicin—ovarian cancer	9.59e-05	0.00096	CcSEcCtD
Crizotinib—Pneumonia—Epirubicin—ovarian cancer	9.51e-05	0.000951	CcSEcCtD
Crizotinib—Paraesthesia—Paclitaxel—ovarian cancer	9.47e-05	0.000947	CcSEcCtD
Crizotinib—Infestation NOS—Epirubicin—ovarian cancer	9.45e-05	0.000946	CcSEcCtD
Crizotinib—Infestation—Epirubicin—ovarian cancer	9.45e-05	0.000946	CcSEcCtD
Crizotinib—TBK1—lymph node—ovarian cancer	9.41e-05	0.00081	CbGeAlD
Crizotinib—PTK2—lymph node—ovarian cancer	9.41e-05	0.00081	CbGeAlD
Crizotinib—Dyspnoea—Paclitaxel—ovarian cancer	9.4e-05	0.000941	CcSEcCtD
Crizotinib—TYK2—lymph node—ovarian cancer	9.35e-05	0.000805	CbGeAlD
Crizotinib—Nausea—Vinorelbine—ovarian cancer	9.31e-05	0.000932	CcSEcCtD
Crizotinib—Dyspepsia—Paclitaxel—ovarian cancer	9.28e-05	0.000929	CcSEcCtD
Crizotinib—Neuropathy peripheral—Epirubicin—ovarian cancer	9.26e-05	0.000927	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	9.26e-05	0.000926	CcSEcCtD
Crizotinib—IRAK1—lymph node—ovarian cancer	9.23e-05	0.000794	CbGeAlD
Crizotinib—Neutropenia—Doxorubicin—ovarian cancer	9.17e-05	0.000918	CcSEcCtD
Crizotinib—Decreased appetite—Paclitaxel—ovarian cancer	9.17e-05	0.000917	CcSEcCtD
Crizotinib—Upper respiratory tract infection—Doxorubicin—ovarian cancer	9.12e-05	0.000912	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Paclitaxel—ovarian cancer	9.1e-05	0.000911	CcSEcCtD
Crizotinib—Fatigue—Paclitaxel—ovarian cancer	9.09e-05	0.00091	CcSEcCtD
Crizotinib—RPS6KB1—lymph node—ovarian cancer	9.05e-05	0.00078	CbGeAlD
Crizotinib—CSF1R—testis—ovarian cancer	9.02e-05	0.000777	CbGeAlD
Crizotinib—Constipation—Paclitaxel—ovarian cancer	9.02e-05	0.000902	CcSEcCtD
Crizotinib—FGR—lymph node—ovarian cancer	9e-05	0.000775	CbGeAlD
Crizotinib—LCK—lymph node—ovarian cancer	9e-05	0.000775	CbGeAlD
Crizotinib—AXL—lymph node—ovarian cancer	8.96e-05	0.000772	CbGeAlD
Crizotinib—Hepatobiliary disease—Epirubicin—ovarian cancer	8.94e-05	0.000894	CcSEcCtD
Crizotinib—Oedema—Docetaxel—ovarian cancer	8.94e-05	0.000894	CcSEcCtD
Crizotinib—Infection—Docetaxel—ovarian cancer	8.88e-05	0.000888	CcSEcCtD
Crizotinib—Weight decreased—Doxorubicin—ovarian cancer	8.87e-05	0.000888	CcSEcCtD
Crizotinib—ABL1—female reproductive system—ovarian cancer	8.84e-05	0.000761	CbGeAlD
Crizotinib—Pneumonia—Doxorubicin—ovarian cancer	8.8e-05	0.00088	CcSEcCtD
Crizotinib—Shock—Docetaxel—ovarian cancer	8.79e-05	0.00088	CcSEcCtD
Crizotinib—Nervous system disorder—Docetaxel—ovarian cancer	8.76e-05	0.000877	CcSEcCtD
Crizotinib—Infestation—Doxorubicin—ovarian cancer	8.75e-05	0.000875	CcSEcCtD
Crizotinib—Infestation NOS—Doxorubicin—ovarian cancer	8.75e-05	0.000875	CcSEcCtD
Crizotinib—Skin disorder—Docetaxel—ovarian cancer	8.68e-05	0.000869	CcSEcCtD
Crizotinib—Bradycardia—Epirubicin—ovarian cancer	8.64e-05	0.000864	CcSEcCtD
Crizotinib—SLK—lymph node—ovarian cancer	8.63e-05	0.000743	CbGeAlD
Crizotinib—Neuropathy peripheral—Doxorubicin—ovarian cancer	8.57e-05	0.000858	CcSEcCtD
Crizotinib—EPHB4—lymph node—ovarian cancer	8.57e-05	0.000737	CbGeAlD
Crizotinib—JAK2—lymph node—ovarian cancer	8.51e-05	0.000732	CbGeAlD
Crizotinib—CDK7—Idarubicin—Epirubicin—ovarian cancer	8.45e-05	0.024	CbGdCrCtD
Crizotinib—CDK7—Daunorubicin—Epirubicin—ovarian cancer	8.45e-05	0.024	CbGdCrCtD
Crizotinib—CDK7—Doxorubicin—Epirubicin—ovarian cancer	8.45e-05	0.024	CbGdCrCtD
Crizotinib—Hypoaesthesia—Epirubicin—ovarian cancer	8.44e-05	0.000845	CcSEcCtD
Crizotinib—EPHA2—lymph node—ovarian cancer	8.4e-05	0.000723	CbGeAlD
Crizotinib—Urinary tract disorder—Epirubicin—ovarian cancer	8.38e-05	0.000838	CcSEcCtD
Crizotinib—Oedema peripheral—Epirubicin—ovarian cancer	8.36e-05	0.000836	CcSEcCtD
Crizotinib—ABL1—bone marrow—ovarian cancer	8.34e-05	0.000718	CbGeAlD
Crizotinib—Body temperature increased—Paclitaxel—ovarian cancer	8.34e-05	0.000834	CcSEcCtD
Crizotinib—Urethral disorder—Epirubicin—ovarian cancer	8.32e-05	0.000832	CcSEcCtD
Crizotinib—Hepatobiliary disease—Doxorubicin—ovarian cancer	8.27e-05	0.000828	CcSEcCtD
Crizotinib—MAP4K5—lymph node—ovarian cancer	8.2e-05	0.000706	CbGeAlD
Crizotinib—TEK—lymph node—ovarian cancer	8.2e-05	0.000706	CbGeAlD
Crizotinib—MAP3K3—lymph node—ovarian cancer	8.2e-05	0.000706	CbGeAlD
Crizotinib—Visual impairment—Epirubicin—ovarian cancer	8.18e-05	0.000818	CcSEcCtD
Crizotinib—ABL1—female gonad—ovarian cancer	8.04e-05	0.000692	CbGeAlD
Crizotinib—Paraesthesia—Docetaxel—ovarian cancer	8.03e-05	0.000803	CcSEcCtD
Crizotinib—Bradycardia—Doxorubicin—ovarian cancer	7.99e-05	0.0008	CcSEcCtD
Crizotinib—ABL1—vagina—ovarian cancer	7.99e-05	0.000688	CbGeAlD
Crizotinib—Dyspnoea—Docetaxel—ovarian cancer	7.97e-05	0.000797	CcSEcCtD
Crizotinib—Eye disorder—Epirubicin—ovarian cancer	7.93e-05	0.000793	CcSEcCtD
Crizotinib—Cardiac disorder—Epirubicin—ovarian cancer	7.87e-05	0.000788	CcSEcCtD
Crizotinib—Dyspepsia—Docetaxel—ovarian cancer	7.87e-05	0.000787	CcSEcCtD
Crizotinib—EPHB6—lymph node—ovarian cancer	7.83e-05	0.000674	CbGeAlD
Crizotinib—CDK7—Epirubicin—Doxorubicin—ovarian cancer	7.82e-05	0.0222	CbGdCrCtD
Crizotinib—CDK7—Idarubicin—Doxorubicin—ovarian cancer	7.82e-05	0.0222	CbGdCrCtD
Crizotinib—CDK7—Daunorubicin—Doxorubicin—ovarian cancer	7.82e-05	0.0222	CbGdCrCtD
Crizotinib—Hypoaesthesia—Doxorubicin—ovarian cancer	7.81e-05	0.000782	CcSEcCtD
Crizotinib—Decreased appetite—Docetaxel—ovarian cancer	7.77e-05	0.000777	CcSEcCtD
Crizotinib—Urinary tract disorder—Doxorubicin—ovarian cancer	7.75e-05	0.000776	CcSEcCtD
Crizotinib—Oedema peripheral—Doxorubicin—ovarian cancer	7.73e-05	0.000774	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Docetaxel—ovarian cancer	7.72e-05	0.000772	CcSEcCtD
Crizotinib—Fatigue—Docetaxel—ovarian cancer	7.71e-05	0.000771	CcSEcCtD
Crizotinib—Urethral disorder—Doxorubicin—ovarian cancer	7.7e-05	0.00077	CcSEcCtD
Crizotinib—Mediastinal disorder—Epirubicin—ovarian cancer	7.65e-05	0.000765	CcSEcCtD
Crizotinib—Constipation—Docetaxel—ovarian cancer	7.64e-05	0.000765	CcSEcCtD
Crizotinib—Arrhythmia—Epirubicin—ovarian cancer	7.58e-05	0.000758	CcSEcCtD
Crizotinib—YES1—lymph node—ovarian cancer	7.57e-05	0.000652	CbGeAlD
Crizotinib—Visual impairment—Doxorubicin—ovarian cancer	7.57e-05	0.000757	CcSEcCtD
Crizotinib—Asthenia—Paclitaxel—ovarian cancer	7.57e-05	0.000757	CcSEcCtD
Crizotinib—STK10—lymph node—ovarian cancer	7.5e-05	0.000646	CbGeAlD
Crizotinib—TAOK3—lymph node—ovarian cancer	7.47e-05	0.000643	CbGeAlD
Crizotinib—Malnutrition—Epirubicin—ovarian cancer	7.39e-05	0.000739	CcSEcCtD
Crizotinib—Eye disorder—Doxorubicin—ovarian cancer	7.34e-05	0.000734	CcSEcCtD
Crizotinib—Cardiac disorder—Doxorubicin—ovarian cancer	7.29e-05	0.000729	CcSEcCtD
Crizotinib—SRC—lymph node—ovarian cancer	7.28e-05	0.000627	CbGeAlD
Crizotinib—Dysgeusia—Epirubicin—ovarian cancer	7.23e-05	0.000724	CcSEcCtD
Crizotinib—Diarrhoea—Paclitaxel—ovarian cancer	7.21e-05	0.000722	CcSEcCtD
Crizotinib—ABL1—testis—ovarian cancer	7.13e-05	0.000614	CbGeAlD
Crizotinib—Mediastinal disorder—Doxorubicin—ovarian cancer	7.08e-05	0.000708	CcSEcCtD
Crizotinib—Body temperature increased—Docetaxel—ovarian cancer	7.06e-05	0.000707	CcSEcCtD
Crizotinib—Arrhythmia—Doxorubicin—ovarian cancer	7.01e-05	0.000702	CcSEcCtD
Crizotinib—Dizziness—Paclitaxel—ovarian cancer	6.97e-05	0.000698	CcSEcCtD
Crizotinib—Vision blurred—Epirubicin—ovarian cancer	6.96e-05	0.000696	CcSEcCtD
Crizotinib—CYP3A5—uterine cervix—ovarian cancer	6.9e-05	0.000594	CbGeAlD
Crizotinib—Malnutrition—Doxorubicin—ovarian cancer	6.83e-05	0.000684	CcSEcCtD
Crizotinib—Anaemia—Epirubicin—ovarian cancer	6.83e-05	0.000683	CcSEcCtD
Crizotinib—Vomiting—Paclitaxel—ovarian cancer	6.7e-05	0.000671	CcSEcCtD
Crizotinib—Dysgeusia—Doxorubicin—ovarian cancer	6.69e-05	0.00067	CcSEcCtD
Crizotinib—Rash—Paclitaxel—ovarian cancer	6.65e-05	0.000665	CcSEcCtD
Crizotinib—Dermatitis—Paclitaxel—ovarian cancer	6.64e-05	0.000665	CcSEcCtD
Crizotinib—Syncope—Epirubicin—ovarian cancer	6.62e-05	0.000663	CcSEcCtD
Crizotinib—Leukopenia—Epirubicin—ovarian cancer	6.61e-05	0.000661	CcSEcCtD
Crizotinib—CSF1R—lymph node—ovarian cancer	6.54e-05	0.000563	CbGeAlD
Crizotinib—Loss of consciousness—Epirubicin—ovarian cancer	6.49e-05	0.00065	CcSEcCtD
Crizotinib—Vision blurred—Doxorubicin—ovarian cancer	6.44e-05	0.000644	CcSEcCtD
Crizotinib—Asthenia—Docetaxel—ovarian cancer	6.41e-05	0.000642	CcSEcCtD
Crizotinib—Anaemia—Doxorubicin—ovarian cancer	6.32e-05	0.000632	CcSEcCtD
Crizotinib—Nausea—Paclitaxel—ovarian cancer	6.26e-05	0.000627	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	6.24e-05	0.000625	CcSEcCtD
Crizotinib—Syncope—Doxorubicin—ovarian cancer	6.13e-05	0.000613	CcSEcCtD
Crizotinib—Leukopenia—Doxorubicin—ovarian cancer	6.12e-05	0.000612	CcSEcCtD
Crizotinib—Diarrhoea—Docetaxel—ovarian cancer	6.11e-05	0.000612	CcSEcCtD
Crizotinib—Oedema—Epirubicin—ovarian cancer	6.03e-05	0.000603	CcSEcCtD
Crizotinib—Loss of consciousness—Doxorubicin—ovarian cancer	6.01e-05	0.000601	CcSEcCtD
Crizotinib—Infection—Epirubicin—ovarian cancer	5.99e-05	0.000599	CcSEcCtD
Crizotinib—Shock—Epirubicin—ovarian cancer	5.93e-05	0.000593	CcSEcCtD
Crizotinib—Nervous system disorder—Epirubicin—ovarian cancer	5.91e-05	0.000591	CcSEcCtD
Crizotinib—Dizziness—Docetaxel—ovarian cancer	5.91e-05	0.000591	CcSEcCtD
Crizotinib—Skin disorder—Epirubicin—ovarian cancer	5.86e-05	0.000586	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	5.78e-05	0.000578	CcSEcCtD
Crizotinib—Vomiting—Docetaxel—ovarian cancer	5.68e-05	0.000569	CcSEcCtD
Crizotinib—Rash—Docetaxel—ovarian cancer	5.63e-05	0.000564	CcSEcCtD
Crizotinib—Dermatitis—Docetaxel—ovarian cancer	5.63e-05	0.000563	CcSEcCtD
Crizotinib—Oedema—Doxorubicin—ovarian cancer	5.58e-05	0.000558	CcSEcCtD
Crizotinib—Infection—Doxorubicin—ovarian cancer	5.54e-05	0.000554	CcSEcCtD
Crizotinib—PLK4—Idarubicin—Epirubicin—ovarian cancer	5.51e-05	0.0156	CbGdCrCtD
Crizotinib—PLK4—Doxorubicin—Epirubicin—ovarian cancer	5.51e-05	0.0156	CbGdCrCtD
Crizotinib—Shock—Doxorubicin—ovarian cancer	5.49e-05	0.000549	CcSEcCtD
Crizotinib—Nervous system disorder—Doxorubicin—ovarian cancer	5.47e-05	0.000547	CcSEcCtD
Crizotinib—Skin disorder—Doxorubicin—ovarian cancer	5.42e-05	0.000542	CcSEcCtD
Crizotinib—Paraesthesia—Epirubicin—ovarian cancer	5.41e-05	0.000542	CcSEcCtD
Crizotinib—Dyspnoea—Epirubicin—ovarian cancer	5.37e-05	0.000538	CcSEcCtD
Crizotinib—Nausea—Docetaxel—ovarian cancer	5.31e-05	0.000531	CcSEcCtD
Crizotinib—Dyspepsia—Epirubicin—ovarian cancer	5.31e-05	0.000531	CcSEcCtD
Crizotinib—Decreased appetite—Epirubicin—ovarian cancer	5.24e-05	0.000524	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Epirubicin—ovarian cancer	5.2e-05	0.000521	CcSEcCtD
Crizotinib—Fatigue—Epirubicin—ovarian cancer	5.2e-05	0.00052	CcSEcCtD
Crizotinib—ABL1—lymph node—ovarian cancer	5.17e-05	0.000445	CbGeAlD
Crizotinib—Constipation—Epirubicin—ovarian cancer	5.15e-05	0.000516	CcSEcCtD
Crizotinib—PLK4—Idarubicin—Doxorubicin—ovarian cancer	5.1e-05	0.0145	CbGdCrCtD
Crizotinib—PLK4—Epirubicin—Doxorubicin—ovarian cancer	5.1e-05	0.0145	CbGdCrCtD
Crizotinib—Paraesthesia—Doxorubicin—ovarian cancer	5.01e-05	0.000501	CcSEcCtD
Crizotinib—Dyspnoea—Doxorubicin—ovarian cancer	4.97e-05	0.000498	CcSEcCtD
Crizotinib—Dyspepsia—Doxorubicin—ovarian cancer	4.91e-05	0.000491	CcSEcCtD
Crizotinib—Decreased appetite—Doxorubicin—ovarian cancer	4.85e-05	0.000485	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Doxorubicin—ovarian cancer	4.82e-05	0.000482	CcSEcCtD
Crizotinib—Fatigue—Doxorubicin—ovarian cancer	4.81e-05	0.000481	CcSEcCtD
Crizotinib—Constipation—Doxorubicin—ovarian cancer	4.77e-05	0.000477	CcSEcCtD
Crizotinib—Body temperature increased—Epirubicin—ovarian cancer	4.77e-05	0.000477	CcSEcCtD
Crizotinib—ABCB1—myometrium—ovarian cancer	4.71e-05	0.000406	CbGeAlD
Crizotinib—CYP3A5—female gonad—ovarian cancer	4.71e-05	0.000405	CbGeAlD
Crizotinib—CYP3A5—vagina—ovarian cancer	4.68e-05	0.000403	CbGeAlD
Crizotinib—ABL1—Doxorubicin—Epirubicin—ovarian cancer	4.63e-05	0.0131	CbGdCrCtD
Crizotinib—ABL1—Idarubicin—Epirubicin—ovarian cancer	4.63e-05	0.0131	CbGdCrCtD
Crizotinib—ABL1—Daunorubicin—Epirubicin—ovarian cancer	4.63e-05	0.0131	CbGdCrCtD
Crizotinib—ABCB1—embryo—ovarian cancer	4.53e-05	0.00039	CbGeAlD
Crizotinib—Body temperature increased—Doxorubicin—ovarian cancer	4.41e-05	0.000441	CcSEcCtD
Crizotinib—Asthenia—Epirubicin—ovarian cancer	4.32e-05	0.000433	CcSEcCtD
Crizotinib—AURKA—Doxorubicin—Epirubicin—ovarian cancer	4.31e-05	0.0122	CbGdCrCtD
Crizotinib—AURKA—Idarubicin—Epirubicin—ovarian cancer	4.31e-05	0.0122	CbGdCrCtD
Crizotinib—AURKA—Daunorubicin—Epirubicin—ovarian cancer	4.31e-05	0.0122	CbGdCrCtD
Crizotinib—ABL1—Idarubicin—Doxorubicin—ovarian cancer	4.28e-05	0.0122	CbGdCrCtD
Crizotinib—ABL1—Epirubicin—Doxorubicin—ovarian cancer	4.28e-05	0.0122	CbGdCrCtD
Crizotinib—ABL1—Daunorubicin—Doxorubicin—ovarian cancer	4.28e-05	0.0122	CbGdCrCtD
Crizotinib—Diarrhoea—Epirubicin—ovarian cancer	4.12e-05	0.000413	CcSEcCtD
Crizotinib—Asthenia—Doxorubicin—ovarian cancer	4e-05	0.0004	CcSEcCtD
Crizotinib—AURKA—Idarubicin—Doxorubicin—ovarian cancer	3.99e-05	0.0113	CbGdCrCtD
Crizotinib—AURKA—Daunorubicin—Doxorubicin—ovarian cancer	3.99e-05	0.0113	CbGdCrCtD
Crizotinib—AURKA—Epirubicin—Doxorubicin—ovarian cancer	3.99e-05	0.0113	CbGdCrCtD
Crizotinib—Dizziness—Epirubicin—ovarian cancer	3.99e-05	0.000399	CcSEcCtD
Crizotinib—CYP3A4—female reproductive system—ovarian cancer	3.88e-05	0.000334	CbGeAlD
Crizotinib—Vomiting—Epirubicin—ovarian cancer	3.83e-05	0.000383	CcSEcCtD
Crizotinib—Diarrhoea—Doxorubicin—ovarian cancer	3.82e-05	0.000382	CcSEcCtD
Crizotinib—Rash—Epirubicin—ovarian cancer	3.8e-05	0.00038	CcSEcCtD
Crizotinib—Dermatitis—Epirubicin—ovarian cancer	3.8e-05	0.00038	CcSEcCtD
Crizotinib—ABCB1—epithelium—ovarian cancer	3.7e-05	0.000318	CbGeAlD
Crizotinib—Dizziness—Doxorubicin—ovarian cancer	3.69e-05	0.000369	CcSEcCtD
Crizotinib—ABCB1—uterine cervix—ovarian cancer	3.67e-05	0.000316	CbGeAlD
Crizotinib—Nausea—Epirubicin—ovarian cancer	3.58e-05	0.000358	CcSEcCtD
Crizotinib—Vomiting—Doxorubicin—ovarian cancer	3.55e-05	0.000355	CcSEcCtD
Crizotinib—Rash—Doxorubicin—ovarian cancer	3.52e-05	0.000352	CcSEcCtD
Crizotinib—Dermatitis—Doxorubicin—ovarian cancer	3.51e-05	0.000352	CcSEcCtD
Crizotinib—ABCB1—decidua—ovarian cancer	3.49e-05	0.000301	CbGeAlD
Crizotinib—ABCB1—endometrium—ovarian cancer	3.32e-05	0.000286	CbGeAlD
Crizotinib—Nausea—Doxorubicin—ovarian cancer	3.31e-05	0.000331	CcSEcCtD
Crizotinib—ABCB1—gonad—ovarian cancer	3.08e-05	0.000265	CbGeAlD
Crizotinib—ABCB1—uterus—ovarian cancer	3.06e-05	0.000263	CbGeAlD
Crizotinib—ABCB1—female reproductive system—ovarian cancer	2.75e-05	0.000237	CbGeAlD
Crizotinib—ABCB1—bone marrow—ovarian cancer	2.59e-05	0.000223	CbGeAlD
Crizotinib—ABCB1—female gonad—ovarian cancer	2.5e-05	0.000215	CbGeAlD
Crizotinib—ABCB1—vagina—ovarian cancer	2.49e-05	0.000214	CbGeAlD
Crizotinib—ABCB1—testis—ovarian cancer	2.22e-05	0.000191	CbGeAlD
Crizotinib—ABCB1—lymph node—ovarian cancer	1.61e-05	0.000138	CbGeAlD
Crizotinib—TYK2—Signaling Pathways—VEGFA—ovarian cancer	7.52e-07	4.57e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—HRAS—ovarian cancer	7.52e-07	4.56e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—MYC—ovarian cancer	7.52e-07	4.56e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CXCL8—ovarian cancer	7.5e-07	4.55e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—KRAS—ovarian cancer	7.49e-07	4.55e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—MYC—ovarian cancer	7.49e-07	4.55e-06	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—AKT1—ovarian cancer	7.49e-07	4.55e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—MAPK1—ovarian cancer	7.46e-07	4.53e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—EGFR—ovarian cancer	7.45e-07	4.53e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—STAT3—ovarian cancer	7.45e-07	4.52e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—NRAS—ovarian cancer	7.43e-07	4.51e-06	CbGpPWpGaD
Crizotinib—TYK2—Disease—IL6—ovarian cancer	7.43e-07	4.51e-06	CbGpPWpGaD
Crizotinib—TYK2—Immune System—AKT1—ovarian cancer	7.42e-07	4.51e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—ERBB2—ovarian cancer	7.4e-07	4.49e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PIK3CG—ovarian cancer	7.39e-07	4.49e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—APC—ovarian cancer	7.39e-07	4.49e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—PIK3CA—ovarian cancer	7.36e-07	4.47e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—MAPK1—ovarian cancer	7.35e-07	4.46e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—EGFR—ovarian cancer	7.35e-07	4.46e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—PIK3CD—ovarian cancer	7.34e-07	4.46e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—MAPK3—ovarian cancer	7.33e-07	4.45e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—MAPK1—ovarian cancer	7.33e-07	4.45e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—EGFR—ovarian cancer	7.33e-07	4.45e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—PIK3CA—ovarian cancer	7.32e-07	4.45e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CDKN1B—ovarian cancer	7.32e-07	4.45e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—YAP1—ovarian cancer	7.31e-07	4.44e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—MAPK3—ovarian cancer	7.3e-07	4.44e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—PIK3CB—ovarian cancer	7.3e-07	4.43e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MTOR—ovarian cancer	7.3e-07	4.43e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—IL6—ovarian cancer	7.3e-07	4.43e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—TP53—ovarian cancer	7.29e-07	4.43e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—IL6—ovarian cancer	7.19e-07	4.37e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—HRAS—ovarian cancer	7.19e-07	4.37e-06	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—AKT1—ovarian cancer	7.19e-07	4.37e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CASP3—ovarian cancer	7.18e-07	4.36e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—CTNNB1—ovarian cancer	7.17e-07	4.35e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—IL2—ovarian cancer	7.17e-07	4.35e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—MYC—ovarian cancer	7.13e-07	4.33e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—TYMS—ovarian cancer	7.12e-07	4.33e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—MAPK3—ovarian cancer	7.11e-07	4.32e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—STAT3—ovarian cancer	7.06e-07	4.29e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—NRAS—ovarian cancer	7.04e-07	4.28e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—KRAS—ovarian cancer	7.04e-07	4.28e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CXCL8—ovarian cancer	7.02e-07	4.26e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—PTEN—ovarian cancer	6.99e-07	4.24e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CCND1—ovarian cancer	6.99e-07	4.24e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—HRAS—ovarian cancer	6.98e-07	4.24e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—MAPK1—ovarian cancer	6.97e-07	4.23e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—HRAS—ovarian cancer	6.97e-07	4.23e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—EGFR—ovarian cancer	6.97e-07	4.23e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—MAPK1—ovarian cancer	6.95e-07	4.22e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—EGFR—ovarian cancer	6.95e-07	4.22e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—KRAS—ovarian cancer	6.94e-07	4.22e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PIK3CG—ovarian cancer	6.93e-07	4.21e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—MYC—ovarian cancer	6.92e-07	4.2e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—KRAS—ovarian cancer	6.92e-07	4.2e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CTNNB1—ovarian cancer	6.92e-07	4.2e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—PIK3CA—ovarian cancer	6.89e-07	4.18e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—IL6—ovarian cancer	6.89e-07	4.18e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CDKN1B—ovarian cancer	6.85e-07	4.16e-06	CbGpPWpGaD
Crizotinib—TYK2—Disease—AKT1—ovarian cancer	6.85e-07	4.16e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—HRAS—ovarian cancer	6.81e-07	4.13e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MMP9—ovarian cancer	6.78e-07	4.12e-06	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—AKT1—ovarian cancer	6.78e-07	4.12e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—HRAS—ovarian cancer	6.78e-07	4.11e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—MAPK1—ovarian cancer	6.77e-07	4.11e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—STAT3—ovarian cancer	6.77e-07	4.11e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—EGFR—ovarian cancer	6.77e-07	4.11e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—NRAS—ovarian cancer	6.75e-07	4.1e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—MAPK3—ovarian cancer	6.74e-07	4.1e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—PTEN—ovarian cancer	6.74e-07	4.09e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—AKT1—ovarian cancer	6.73e-07	4.09e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CASP3—ovarian cancer	6.72e-07	4.08e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—IL2—ovarian cancer	6.71e-07	4.07e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—IL6—ovarian cancer	6.68e-07	4.05e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—IL6—ovarian cancer	6.67e-07	4.05e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—AKT1—ovarian cancer	6.64e-07	4.03e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—KRAS—ovarian cancer	6.59e-07	4e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—KRAS—ovarian cancer	6.56e-07	3.99e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—MYC—ovarian cancer	6.56e-07	3.98e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CCND1—ovarian cancer	6.54e-07	3.97e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—IL6—ovarian cancer	6.52e-07	3.96e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PIK3CD—ovarian cancer	6.5e-07	3.94e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—IL6—ovarian cancer	6.49e-07	3.94e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—ERBB2—ovarian cancer	6.48e-07	3.94e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CTNNB1—ovarian cancer	6.47e-07	3.93e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—PIK3CA—ovarian cancer	6.47e-07	3.93e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—MAPK3—ovarian cancer	6.47e-07	3.93e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—MAPK1—ovarian cancer	6.42e-07	3.9e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—EGFR—ovarian cancer	6.42e-07	3.9e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MTOR—ovarian cancer	6.4e-07	3.88e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—PIK3CB—ovarian cancer	6.4e-07	3.88e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—KRAS—ovarian cancer	6.39e-07	3.88e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—PIK3CA—ovarian cancer	6.38e-07	3.87e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—HRAS—ovarian cancer	6.37e-07	3.87e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—PIK3CA—ovarian cancer	6.36e-07	3.86e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—AKT1—ovarian cancer	6.35e-07	3.86e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MMP9—ovarian cancer	6.35e-07	3.85e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—PTEN—ovarian cancer	6.31e-07	3.83e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—TP53—ovarian cancer	6.26e-07	3.8e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—STAT3—ovarian cancer	6.25e-07	3.79e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—NRAS—ovarian cancer	6.23e-07	3.79e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—TP53—ovarian cancer	6.17e-07	3.75e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—AKT1—ovarian cancer	6.16e-07	3.74e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—AKT1—ovarian cancer	6.16e-07	3.74e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—MAPK1—ovarian cancer	6.15e-07	3.74e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—EGFR—ovarian cancer	6.15e-07	3.74e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CXCL8—ovarian cancer	6.15e-07	3.73e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—IL6—ovarian cancer	6.1e-07	3.7e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PIK3CD—ovarian cancer	6.09e-07	3.7e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—VEGFA—ovarian cancer	6.09e-07	3.7e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—KRAS—ovarian cancer	6.06e-07	3.68e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—PIK3CA—ovarian cancer	6.05e-07	3.67e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—PIK3CA—ovarian cancer	6.03e-07	3.66e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—STAT3—ovarian cancer	6.03e-07	3.66e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—NRAS—ovarian cancer	6.02e-07	3.65e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—AKT1—ovarian cancer	6.01e-07	3.65e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CDKN1B—ovarian cancer	6e-07	3.64e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—HRAS—ovarian cancer	5.99e-07	3.63e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—AKT1—ovarian cancer	5.98e-07	3.63e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—MAPK3—ovarian cancer	5.97e-07	3.63e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—FASN—ovarian cancer	5.96e-07	3.62e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—HRAS—ovarian cancer	5.9e-07	3.58e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CASP3—ovarian cancer	5.88e-07	3.57e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—HRAS—ovarian cancer	5.88e-07	3.57e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IL2—ovarian cancer	5.87e-07	3.57e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—PIK3CA—ovarian cancer	5.87e-07	3.57e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—SLC5A5—ovarian cancer	5.86e-07	3.56e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—TP53—ovarian cancer	5.85e-07	3.55e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—KRAS—ovarian cancer	5.81e-07	3.53e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—MYC—ovarian cancer	5.81e-07	3.53e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MAPK3—ovarian cancer	5.76e-07	3.5e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—CAV1—ovarian cancer	5.74e-07	3.49e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—ERBB2—ovarian cancer	5.74e-07	3.48e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—IL6—ovarian cancer	5.73e-07	3.48e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CCND1—ovarian cancer	5.73e-07	3.48e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—VEGFA—ovarian cancer	5.7e-07	3.46e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—TP53—ovarian cancer	5.68e-07	3.45e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—MAPK1—ovarian cancer	5.68e-07	3.45e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—EGFR—ovarian cancer	5.68e-07	3.45e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CTNNB1—ovarian cancer	5.67e-07	3.44e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PIK3CB—ovarian cancer	5.66e-07	3.44e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MTOR—ovarian cancer	5.66e-07	3.44e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—SLC2A1—ovarian cancer	5.66e-07	3.44e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—IL6—ovarian cancer	5.65e-07	3.43e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—STAT3—ovarian cancer	5.64e-07	3.43e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—NRAS—ovarian cancer	5.63e-07	3.42e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—IL6—ovarian cancer	5.63e-07	3.42e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—AKT1—ovarian cancer	5.63e-07	3.42e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MYC—ovarian cancer	5.6e-07	3.4e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—HRAS—ovarian cancer	5.6e-07	3.4e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—HRAS—ovarian cancer	5.58e-07	3.39e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—PIK3CA—ovarian cancer	5.57e-07	3.38e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MMP9—ovarian cancer	5.56e-07	3.38e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—PTEN—ovarian cancer	5.53e-07	3.36e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MAPK1—ovarian cancer	5.48e-07	3.33e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—EGFR—ovarian cancer	5.48e-07	3.33e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CXCL8—ovarian cancer	5.44e-07	3.3e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—HRAS—ovarian cancer	5.43e-07	3.3e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CYP1B1—ovarian cancer	5.43e-07	3.3e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MAPK3—ovarian cancer	5.39e-07	3.27e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—KRAS—ovarian cancer	5.37e-07	3.26e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—IL6—ovarian cancer	5.36e-07	3.25e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—IL6—ovarian cancer	5.34e-07	3.24e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—PIK3CA—ovarian cancer	5.34e-07	3.24e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CDKN1B—ovarian cancer	5.31e-07	3.23e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PIK3CB—ovarian cancer	5.31e-07	3.22e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—AKT1—ovarian cancer	5.28e-07	3.21e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MYC—ovarian cancer	5.24e-07	3.18e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PIK3CG—ovarian cancer	5.23e-07	3.17e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—AKT1—ovarian cancer	5.21e-07	3.16e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CASP3—ovarian cancer	5.21e-07	3.16e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—IL6—ovarian cancer	5.2e-07	3.16e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IL2—ovarian cancer	5.2e-07	3.16e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—AKT1—ovarian cancer	5.19e-07	3.15e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—KRAS—ovarian cancer	5.18e-07	3.14e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—HRAS—ovarian cancer	5.15e-07	3.13e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MAPK1—ovarian cancer	5.13e-07	3.12e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—EGFR—ovarian cancer	5.13e-07	3.11e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CCND1—ovarian cancer	5.07e-07	3.08e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CTNNB1—ovarian cancer	5.02e-07	3.05e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—VEGFA—ovarian cancer	4.99e-07	3.03e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—AKT1—ovarian cancer	4.94e-07	3e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—STAT3—ovarian cancer	4.94e-07	3e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—HRAS—ovarian cancer	4.94e-07	3e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—NRAS—ovarian cancer	4.93e-07	2.99e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—IL6—ovarian cancer	4.93e-07	2.99e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—PIK3CA—ovarian cancer	4.93e-07	2.99e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—AKT1—ovarian cancer	4.93e-07	2.99e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MMP9—ovarian cancer	4.92e-07	2.99e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PTEN—ovarian cancer	4.89e-07	2.97e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—KRAS—ovarian cancer	4.85e-07	2.94e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	4.81e-07	2.92e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—AKT1—ovarian cancer	4.8e-07	2.91e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—PIK3CA—ovarian cancer	4.76e-07	2.89e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—IL6—ovarian cancer	4.73e-07	2.87e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MAPK3—ovarian cancer	4.72e-07	2.87e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TP53—ovarian cancer	4.6e-07	2.79e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PIK3CD—ovarian cancer	4.6e-07	2.79e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MYC—ovarian cancer	4.59e-07	2.79e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PTEN—ovarian cancer	4.59e-07	2.79e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—HRAS—ovarian cancer	4.56e-07	2.77e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—AKT1—ovarian cancer	4.55e-07	2.76e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MAPK1—ovarian cancer	4.49e-07	2.73e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—EGFR—ovarian cancer	4.49e-07	2.73e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ABCB1—ovarian cancer	4.47e-07	2.71e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—PIK3CA—ovarian cancer	4.45e-07	2.7e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—VEGFA—ovarian cancer	4.42e-07	2.68e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—HRAS—ovarian cancer	4.4e-07	2.67e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—TYMS—ovarian cancer	4.39e-07	2.67e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—STAT3—ovarian cancer	4.38e-07	2.66e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—NRAS—ovarian cancer	4.37e-07	2.65e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—IL6—ovarian cancer	4.37e-07	2.65e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—AKT1—ovarian cancer	4.36e-07	2.65e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TP53—ovarian cancer	4.31e-07	2.62e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—KRAS—ovarian cancer	4.24e-07	2.58e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—IL6—ovarian cancer	4.21e-07	2.56e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MAPK3—ovarian cancer	4.18e-07	2.54e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—HRAS—ovarian cancer	4.12e-07	2.5e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MYC—ovarian cancer	4.07e-07	2.47e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—AKT1—ovarian cancer	4.03e-07	2.45e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PIK3CB—ovarian cancer	4.01e-07	2.43e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MAPK1—ovarian cancer	3.98e-07	2.42e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—EGFR—ovarian cancer	3.98e-07	2.42e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—IL6—ovarian cancer	3.94e-07	2.39e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—PIK3CA—ovarian cancer	3.9e-07	2.37e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—AKT1—ovarian cancer	3.89e-07	2.36e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TP53—ovarian cancer	3.77e-07	2.29e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—KRAS—ovarian cancer	3.76e-07	2.28e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—AKT1—ovarian cancer	3.64e-07	2.21e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—HRAS—ovarian cancer	3.61e-07	2.19e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CAV1—ovarian cancer	3.54e-07	2.15e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PTEN—ovarian cancer	3.46e-07	2.1e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IL6—ovarian cancer	3.45e-07	2.1e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PIK3CA—ovarian cancer	3.45e-07	2.1e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TP53—ovarian cancer	3.34e-07	2.03e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PIK3CA—ovarian cancer	3.24e-07	1.97e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PIK3CG—ovarian cancer	3.22e-07	1.96e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—HRAS—ovarian cancer	3.19e-07	1.94e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—AKT1—ovarian cancer	3.19e-07	1.93e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IL6—ovarian cancer	3.06e-07	1.86e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PIK3CD—ovarian cancer	2.83e-07	1.72e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—AKT1—ovarian cancer	2.82e-07	1.71e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—AKT1—ovarian cancer	2.64e-07	1.61e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PIK3CB—ovarian cancer	2.47e-07	1.5e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PIK3CA—ovarian cancer	2.44e-07	1.48e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PTEN—ovarian cancer	2.13e-07	1.3e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—AKT1—ovarian cancer	2e-07	1.21e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PIK3CA—ovarian cancer	1.5e-07	9.14e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—AKT1—ovarian cancer	1.23e-07	7.46e-07	CbGpPWpGaD
